Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and colorectal cancer prevention

Current Opinion in Gastroenterology

Volumn 17, Issue 1, 2001, Pages 65-71

  DuBois, R N ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SULINDAC;

ADENOMATOUS POLYP; CANCER PREVENTION; CANCER SCREENING; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; FAMILIAL DISEASE; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC MODEL; HUMAN; NONHUMAN; POLYPOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035141681     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200101000-00013     Document Type: Review

References (82)

1. Cancer statistics
2. Epidemiology and molecular genetics of colorectal cancer
3. A genetic model for colorectal tumongenesis
4. Hereditary nonpolyposis colorectal cancer
5. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
6. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer
7. Mutations of a routs homolog in hereditary nonpolyposis colorectal cancer
8. Accumulation of multiple mutations in tumor suppressor genes during colorectal tumorigenesis in HNPCC patients
9. Tumor suppressor activity of the TGF-beta pathway in human cancers
10. Both transforming growth factor-beta and substrate release are inducers of apoptosis in a human colon adenoma cell line
11. TGF-beta signaling and cancer: Structural and functional consequences of mutations in Smads
12. HNPCC associated with germline mutation in the TGF-beta type II receptor gene
13. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
14. A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms
15. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells
16. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-beta
17. Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells
18. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells
19. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
20. A structural basis for mutational inactivation of the tumor suppressor Smad4
21. Mutations in the tumor suppressors smad2 and smad4 inactivate transforming growth factor beta signaling by targeting smads to the ubiquitin-proteasome pathway
22. The gene for familiar polyposis coli maps to the long arm of chromosome 5
23. Localization of the gene for familial adenomatous polyposis on chromosome 5
24. Identification and characterization of the familial adenomatous polyposis coli gene
25. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APO gene
26. APC mutations occur early during cotorectal tumongenesis
27. Lessons from hereditary colorectal cancer
28. Molecular determinants of dysplasia in colorectal lesions
29. Apoptosis and APC in colorectal tumorigenesis
30. Association of the APC gene product: With beta-catenin
31. Association of the APC tumor suppressor protein with catenins
32. Biology of the adenomatous polyposis coli tumor suppressor
33. Cadherin-catenin complex: Protein interactions and their implications for cadherin function
34. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein
35. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC·/- colon carcinoma
36. Functional interaction of beta-catenin with the transcription factor LEF-1
37. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos
38. b)?>Beta-catenin is a target for the ubiquitin-proteasome pathway
39. Identification of c-MYC as a target of the APC pathway
40. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
41. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway
42. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors
43. Regulation of COX-2 and penostin by Wnt-3 in mouse mammary epithelial cells
44. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells
45. PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
46. Sulindac for polyposis of the colon
47. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
48. Treatment of colonic and rectal adenomas with sulidac in familial adenomatous polyposis
49. Randomized controlled trial of the effect of sulidac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
50. Aspirin use and reduced risk of fatal colon cancer
51. Identification of a phorbol ester repressible v-src-inducible gene
52. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
53. Prostaglandin endoperoxide synthase: Why two isoforms?
54. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
55. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
56. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
57. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
58. Prostaglandin E2 levels and lymphocyte subsets in portal venous drainage of colorectal cancers
59. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2
60. Suppression of intestinal polyposis in Apc detal716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
61. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
62. Elevated cyclooxygenase-2 levels in Min mouse adenomas
63. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
64. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
65. Use of azoxymethane-induced foci of aberrant in rat colon to identify potential cancer chemopreventive agents
66. The effect of calecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
67. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR-delta
68. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid- activated transcription factor
69. PPAR gamma promote monocyte/macrophage differentiation and uptake of oxidized LDL
70. The nuclear eicosanoid receptor. PPAR gamma, is expressed in colonic cancers
71. The organization, promoter analysis, and expression of the human PPAR gamma gene
72. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma
73. Activation of PPARgamma leads to inhibit of anchorage-independent growth of human colorectal cancer cells
74. Loss-of-function mutations in PPAR gamma associated with human colon cancer
75. Activation of the peroxisome proliferation-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
76. Activators of the nuclear receptor PPARgamma enhance colon polyp formation
77. PAX8-PPAR gamma 1 fusion in oncogene human thyroid carcinoma
78. Nitric oxide synthases: Roles, tolls, and controls
79. Nitric oxide: Novel biology with clinical relevance
80. NO at work
81. Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue
82. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane